AbCellera Biologics (ABCL) Set to Announce Earnings on Tuesday

AbCellera Biologics (NASDAQ:ABCL) is scheduled to be issuing its quarterly earnings data after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

AbCellera Biologics (NASDAQ:ABCL) last released its quarterly earnings data on Tuesday, February 20th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The business had revenue of $9.18 million during the quarter, compared to the consensus estimate of $9.58 million. AbCellera Biologics had a negative net margin of 384.99% and a negative return on equity of 12.36%. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Price Performance

NASDAQ:ABCL opened at $3.84 on Tuesday. AbCellera Biologics has a one year low of $3.62 and a one year high of $8.05. The company has a market cap of $1.12 billion, a PE ratio of -7.38 and a beta of 0.36. The firm has a 50-day moving average of $4.53 and a 200-day moving average of $4.80.

Wall Street Analysts Forecast Growth

ABCL has been the subject of several analyst reports. Stifel Nicolaus lowered their target price on shares of AbCellera Biologics from $21.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 21st. Benchmark raised AbCellera Biologics from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a research report on Thursday, February 22nd. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $15.86.

About AbCellera Biologics

AbCellera Biologics Inc builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis.